Rodrigo Abdalla

NowCM is the leading market infrastructure and issuance provider within the primary debt capital markets. It offers a market-leading, cloud-native data platform for creating, negotiating, and managing debt, along with an end-to-end secure, digital workflow platform. These tools enable all participants in the primary bond markets to collaborate in real-time, fostering an open and cooperative environment. NowCM facilitate access to primary markets for inaugural and infrequent issuers through its Treasury-as-a-Service (TaaS) facility. This entity is regulated by the CSSF in Luxembourg and operates as a “funding subsidiary” using standardised yet flexible documentation and fully automated digital workflows. NowCM’s 360-degree suite of services is completed by a multi-lateral trading facility (MTF) that NowCM owns and operates. It stands as the world’s first and only regulated primary marketplace, subject to the supervision of the ACPR and AMF in France.

Pear Bio analyzes patient tumor samples and data with a proprietary computational biology platform to deconvolute complex cancer biology and drive patient-centric functional precision medicine and drug discovery. Our ultimate goal is to optimally allocate approved treatments to cancer patients who will benefit from them, while creating novel therapies that are purpose-designed for patients who dont respond to available treatments. The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples with matched blood into 3D immune-microtumors to test potential treatment options and combinations ex vivo. A proprietary computer vision/DL pipeline finds image-based spatial biomarkers in time-course 3D microscopy data of patient 3D immune-microtumors. Each treatment option is compared using these image biomarkers to predict which treatments have high potential efficacy for each patient. Patient data and excess tissue/blood feed into a multi-omics pipeline, which allows us to find novel druggable targets in patients who dont respond to approved therapies. These targets are then developed into our in-house drug discovery pipeline, which eventually feeds back into clinical care through our predictive biomarker platform.

Cognoptix is pioneering a new way to see Alzheimer's disease (AD): a low-cost, practical and non-invasive eye scan that detects beta-amyloid deposits in the lens. Amyloid is the earliest biomarker of AD, and our system can detect it years or decades before amyloid appears in the brain.

Antler is one of the most active early-stage investors globally. The firm leads in ‘Day Zero’ investing, an approach to venture capital focused on partnering with founders pre-launch. Antler systematically removes capital and network constraints for early-stage technology entrepreneurs by providing co-founder matching, deep business model validation, initial capital, expansion support, and follow-on funding. The firm is present in 27 cities across most leading technology ecosystems globally and has made over 1,300 investments into early-stage startups. Antler has been repeatedly recognized by Pitchbook as the world’s most active angel and seed-stage investor.

Amalytics Software is a UK-based business that specialises in developing and deploying SaaS-based Cost Management software for global businesses operating a complex technology environment. With reputed clients across the UK and Europe, Amalytics Software's state-of-the-art product CostLens enables its clients to efficiently manage costs through greater Cost Transparency, optimise Technology costs, and increase returns on its investments. Learn more at www.amalytics.co

The Harvard Business School Alumni Angels of London is a Harvard University affiliated group committed to investing in early stage and growing businesses and supporting the rapidly growing UK and European start-up ecosystem. We are led buy a seasoned group of volunteer executives and investors who are passionate about building value through innovation and entrepreneurship, and if you share our passion, and want to learn more either as an entrepreneur or angel investor, we invite you to contact us.

Clicksign is an online platform to sign documents. Simple, fast, safe, and juridically valid in Brazil, it helps you close deals more efficiently, reducing bureaucracy. From sales and purchase orders to long-term contracts and internal approvals. Visit http://www.clicksign.com/ for more information.

HBS Alumni Angels of Brazil is the local Brazilian Chapter of HBS Alumni Angels, a global nonprofit organization comprised of Harvard alumni interested in investing in high-potential early stage companies. HBS Alumni Angels of Brazil is based in Sao Paulo and run by to active angels investors. The club also has committees dedicated to specific activities and run by its club members. It will be incorporated as a non-profit club under the Brazilian law. HBS Alumni Angels is open to all Harvard alumni and others affiliated with the university, not just HBS graduates. It is not an investment fund and it does not raise money to invest in behalf of its members or other people. It is a club that helps its members to seed and develop early stage companies by themselves, usually in a syndicated format between its members. To submit a business plan for funding by HBS Alumni Angels of Brazil, please visit our Gust website at http://gust.com/angel-group/harvard-business-school-angels-of-brazil . Please note: Our group invest in companies regardless of whether any of the management or owners are Harvard alumni.

A Tamarin é uma plataforma premium de saúde clínica e comportamental focada em resolver o maior gargalo financeiro do emagrecimento moderno: a adesão ao tratamento. Enquanto dados reais mostram que até 68% dos pacientes abandonam o GLP-1 no primeiro ano, a Tamarin une a prescrição médica com o acompanhamento diário do nosso assistente virtual. Nós transformamos prescrições de alto custo e alta evasão em mudanças de vida sustentáveis, garantindo manutenção de resultados clínicos para os pacientes e proteção do ROI de saúde para nossos parceiros corporativos. Saúde que cabe no seu dia. Resultados que duram uma vida. O começo: Em 2021, um endocrinologista disse a Mel que ela estava mentindo. Que era impossível treinar como ela treinava, comer como ela comia, e ainda ganhar peso. Ele não perguntou sobre a tireoide. Não perguntou sobre perimenopausa. Não investigou se a exaustão, o peso e os marcadores metabólicos estavam conectados. Ele já tinha o diagnóstico antes dela terminar de falar: esforço insuficiente. O sistema está errado. Os tratamentos que abordam os mecanismos metabólicos por trás do peso, da energia e da saúde hormonal existem. São aprovados pela ANVISA. O acesso a eles permanece fragmentado, caro, e, quando uma mulher finalmente alcança um médico, condicional a ela convencê-lo de que já se esforçou o suficiente. Quando Mel finalmente recebeu o tratamento certo, sua tireoide estabilizou pela primeira vez em vinte anos. O peso mudou. A energia voltou. Isso não é uma história de falha pessoal. É uma falha estrutural. Por que Tamarin? Em 1970, restavam menos de 200 micos-leões-dourados no Brasil. Hoje, mais de 4.800. A espécie não se recuperou por resiliência. Recuperou-se porque um programa coordenado, brasileiro, de décadas, baseado em ciência, finalmente aplicou a intervenção certa na escala certa. O esforço individual já estava esgotado. O que mudou o desfecho foi estrutural.

The attention economy is the greatest commercial force on the planet. 50 million creators, athletes and talent sit on the highest-trust audiences in history and their fans signal purchase intent every single day in comments, DMs and community posts. The problem is infrastructure. Tracking that intent manually is impossible. Billions are left on the table. Converting it into structured, scalable commerce requires capabilities most attention-driven businesses cannot build alone, no matter whether you are a creator with a million followers, an athlete with a global fanbase, or an agency managing both. GYST fixes this. Our AI reads audience signals across social platforms simultaneously, identifies validated commerce opportunities in under 30 seconds, and deploys autonomous agents to execute the full commerce loop, from product concept, supplier sourcing, store build, marketing, payment and fulfilment. The creator or athlete approves. GYST handles everything else. For merchants and commerce partners, GYST surfaces creator audiences that are already generating purchase intent around your product category and connects that demand directly to your existing infrastructure. We bring you buyers, not browsers. Our intelligence layer sits upstream of every commerce platform, integrating with TikTok, Instagram, YouTube and more, making existing infrastructure more valuable rather than replacing it. We are the OS, not the storefront. Agentic commerce grew 6,900% last year. The pipes for the attention economy havent been built yet. Thats why GYST is here.

NowCM is the leading market infrastructure and issuance provider within the primary debt capital markets. It offers a market-leading, cloud-native data platform for creating, negotiating, and managing debt, along with an end-to-end secure, digital workflow platform. These tools enable all participants in the primary bond markets to collaborate in real-time, fostering an open and cooperative environment. NowCM facilitate access to primary markets for inaugural and infrequent issuers through its Treasury-as-a-Service (TaaS) facility. This entity is regulated by the CSSF in Luxembourg and operates as a “funding subsidiary” using standardised yet flexible documentation and fully automated digital workflows. NowCM’s 360-degree suite of services is completed by a multi-lateral trading facility (MTF) that NowCM owns and operates. It stands as the world’s first and only regulated primary marketplace, subject to the supervision of the ACPR and AMF in France.